In June 2020, FDA released Guidance for Industry (GFI) entitled “Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing”. FDA is issuing this guidance to provide recommendations to drug and biological product manufacturers regarding:
- Manufacturing controls to prevent contamination of drugs,
- Risk assessment of SARS-CoV-2 as it relates to drug safety or quality,
- Continuity of manufacturing operations.
- Read complete blog on :- https://veeprho.com/blog/good-manufacturing-practice-gmp-practice-considerations-for-responding-to-covid-19/
No comments:
Post a Comment